Stem definition | Drug id | CAS RN |
---|---|---|
monobactam antibiotics | 279 | 78110-38-0 |
Dose | Unit | Route |
---|---|---|
0.23 | g | Inhal.solution |
4 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 10 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 68 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 305.44 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 1 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.18 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 1.50 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.40 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1.50 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 31, 1986 | FDA | BRISTOL MYERS SQUIBB |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Infective pulmonary exacerbation of cystic fibrosis | 1676.40 | 24.32 | 346 | 6253 | 7563 | 50590962 |
Cystic fibrosis | 421.16 | 24.32 | 93 | 6506 | 2771 | 50595754 |
Death | 259.26 | 24.32 | 261 | 6338 | 325118 | 50273407 |
Lung transplant | 215.92 | 24.32 | 54 | 6545 | 2771 | 50595754 |
Pulmonary function test decreased | 211.00 | 24.32 | 55 | 6544 | 3333 | 50595192 |
Haemoptysis | 207.19 | 24.32 | 89 | 6510 | 25484 | 50573041 |
Hospitalisation | 194.70 | 24.32 | 117 | 6482 | 67820 | 50530705 |
Cystic fibrosis respiratory infection suppression | 125.33 | 24.32 | 23 | 6576 | 257 | 50598268 |
Respiratory failure | 110.68 | 24.32 | 93 | 6506 | 91088 | 50507437 |
Cough | 98.36 | 24.32 | 138 | 6461 | 241126 | 50357399 |
Pseudomonas infection | 97.15 | 24.32 | 39 | 6560 | 9391 | 50589134 |
Lung disorder | 81.18 | 24.32 | 58 | 6541 | 44741 | 50553784 |
Off label use | 78.46 | 24.32 | 183 | 6416 | 474243 | 50124282 |
Sputum increased | 64.06 | 24.32 | 19 | 6580 | 1848 | 50596677 |
Infection | 60.26 | 24.32 | 92 | 6507 | 172862 | 50425663 |
Bronchial secretion retention | 54.55 | 24.32 | 16 | 6583 | 1497 | 50597028 |
Distal intestinal obstruction syndrome | 54.42 | 24.32 | 12 | 6587 | 353 | 50598172 |
Sinus operation | 52.74 | 24.32 | 16 | 6583 | 1680 | 50596845 |
Bacterial disease carrier | 49.67 | 24.32 | 13 | 6586 | 798 | 50597727 |
Bronchiectasis | 49.52 | 24.32 | 25 | 6574 | 10258 | 50588267 |
Eosinophilia | 47.86 | 24.32 | 30 | 6569 | 18622 | 50579903 |
Pneumonia | 45.78 | 24.32 | 130 | 6469 | 378271 | 50220254 |
Drug reaction with eosinophilia and systemic symptoms | 45.13 | 24.32 | 34 | 6565 | 28390 | 50570135 |
Forced expiratory volume decreased | 44.65 | 24.32 | 18 | 6581 | 4376 | 50594149 |
Pancreatic failure | 43.95 | 24.32 | 12 | 6587 | 866 | 50597659 |
Transplant | 42.62 | 24.32 | 11 | 6588 | 639 | 50597886 |
Pulmonary haemorrhage | 37.89 | 24.32 | 18 | 6581 | 6474 | 50592051 |
Nonspecific reaction | 35.59 | 24.32 | 12 | 6587 | 1767 | 50596758 |
Chest discomfort | 34.61 | 24.32 | 51 | 6548 | 92671 | 50505854 |
Superinfection | 33.89 | 24.32 | 12 | 6587 | 2044 | 50596481 |
Bronchospasm | 33.43 | 24.32 | 22 | 6577 | 14832 | 50583693 |
Treatment noncompliance | 32.93 | 24.32 | 29 | 6570 | 30121 | 50568404 |
Productive cough | 32.23 | 24.32 | 37 | 6562 | 52657 | 50545868 |
Pathogen resistance | 27.88 | 24.32 | 14 | 6585 | 5675 | 50592850 |
Drug resistance | 26.40 | 24.32 | 21 | 6578 | 18968 | 50579557 |
Pneumothorax | 25.00 | 24.32 | 18 | 6581 | 14016 | 50584509 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Infective pulmonary exacerbation of cystic fibrosis | 889.77 | 24.65 | 205 | 4581 | 6031 | 29563710 |
Cystic fibrosis | 350.48 | 24.65 | 74 | 4712 | 1418 | 29568323 |
Lung transplant | 277.98 | 24.65 | 63 | 4723 | 1693 | 29568048 |
Hospitalisation | 135.02 | 24.65 | 87 | 4699 | 45901 | 29523840 |
Death | 114.49 | 24.65 | 200 | 4586 | 341884 | 29227857 |
Pulmonary function test decreased | 88.47 | 24.65 | 31 | 4755 | 4132 | 29565609 |
Cystic fibrosis respiratory infection suppression | 87.93 | 24.65 | 17 | 4769 | 203 | 29569538 |
Haemoptysis | 80.30 | 24.65 | 54 | 4732 | 30496 | 29539245 |
Pseudomonas infection | 74.61 | 24.65 | 36 | 4750 | 10816 | 29558925 |
Eosinophilia | 72.60 | 24.65 | 45 | 4741 | 22116 | 29547625 |
Respiratory failure | 61.46 | 24.65 | 77 | 4709 | 97054 | 29472687 |
Sputum increased | 55.35 | 24.65 | 18 | 4768 | 1909 | 29567832 |
Cystic fibrosis related diabetes | 50.65 | 24.65 | 10 | 4776 | 134 | 29569607 |
Productive cough | 49.99 | 24.65 | 41 | 4745 | 31218 | 29538523 |
Infection | 48.75 | 24.65 | 61 | 4725 | 76690 | 29493051 |
Hepatic cytolysis | 46.46 | 24.65 | 24 | 4762 | 8323 | 29561418 |
Pathogen resistance | 41.36 | 24.65 | 22 | 4764 | 8094 | 29561647 |
Infective exacerbation of bronchiectasis | 39.90 | 24.65 | 10 | 4776 | 414 | 29569327 |
Lung disorder | 38.73 | 24.65 | 35 | 4751 | 30327 | 29539414 |
Leukocytosis | 38.63 | 24.65 | 30 | 4756 | 21112 | 29548629 |
Rash maculo-papular | 34.97 | 24.65 | 30 | 4756 | 24259 | 29545482 |
Condition aggravated | 34.28 | 24.65 | 74 | 4712 | 146221 | 29423520 |
Distal intestinal obstruction syndrome | 33.76 | 24.65 | 8 | 4778 | 261 | 29569480 |
Off label use | 32.14 | 24.65 | 114 | 4672 | 300686 | 29269055 |
Forced expiratory volume decreased | 31.05 | 24.65 | 13 | 4773 | 2800 | 29566941 |
Drug reaction with eosinophilia and systemic symptoms | 29.43 | 24.65 | 29 | 4757 | 27963 | 29541778 |
Cough | 27.28 | 24.65 | 62 | 4724 | 126665 | 29443076 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Infective pulmonary exacerbation of cystic fibrosis | 1984.85 | 20.89 | 437 | 9182 | 11359 | 64477754 |
Cystic fibrosis | 569.02 | 20.89 | 126 | 9493 | 3308 | 64485805 |
Lung transplant | 395.37 | 20.89 | 97 | 9522 | 4011 | 64485102 |
Pulmonary function test decreased | 244.15 | 20.89 | 73 | 9546 | 6388 | 64482725 |
Haemoptysis | 223.69 | 20.89 | 120 | 9499 | 48928 | 64440185 |
Death | 210.22 | 20.89 | 305 | 9314 | 482400 | 64006713 |
Hospitalisation | 198.02 | 20.89 | 129 | 9490 | 75078 | 64414035 |
Cystic fibrosis respiratory infection suppression | 149.73 | 20.89 | 29 | 9590 | 382 | 64488731 |
Pseudomonas infection | 129.64 | 20.89 | 60 | 9559 | 17823 | 64471290 |
Eosinophilia | 124.49 | 20.89 | 75 | 9544 | 38001 | 64451112 |
Sputum increased | 103.19 | 20.89 | 33 | 9586 | 3602 | 64485511 |
Respiratory failure | 89.48 | 20.89 | 115 | 9504 | 161068 | 64328045 |
Off label use | 88.21 | 20.89 | 249 | 9370 | 632557 | 63856556 |
Distal intestinal obstruction syndrome | 81.75 | 20.89 | 19 | 9600 | 619 | 64488494 |
Cough | 74.82 | 20.89 | 149 | 9470 | 301999 | 64187114 |
Lung disorder | 74.34 | 20.89 | 66 | 9553 | 60634 | 64428479 |
Drug reaction with eosinophilia and systemic symptoms | 72.53 | 20.89 | 62 | 9557 | 54155 | 64434958 |
Forced expiratory volume decreased | 65.70 | 20.89 | 28 | 9591 | 6839 | 64482274 |
Infective exacerbation of bronchiectasis | 63.58 | 20.89 | 16 | 9603 | 732 | 64488381 |
Pancreatic failure | 61.70 | 20.89 | 18 | 9601 | 1442 | 64487671 |
Bronchiectasis | 57.18 | 20.89 | 32 | 9587 | 14108 | 64475005 |
Pathogen resistance | 55.16 | 20.89 | 30 | 9589 | 12513 | 64476600 |
Pneumonia | 53.75 | 20.89 | 194 | 9425 | 559382 | 63929731 |
Productive cough | 51.58 | 20.89 | 59 | 9560 | 73144 | 64415969 |
Sinus operation | 50.63 | 20.89 | 16 | 9603 | 1679 | 64487434 |
Bacterial disease carrier | 45.25 | 20.89 | 13 | 9606 | 986 | 64488127 |
Hepatic cytolysis | 44.15 | 20.89 | 27 | 9592 | 14022 | 64475091 |
Cystic fibrosis related diabetes | 43.32 | 20.89 | 9 | 9610 | 172 | 64488941 |
Transplant | 42.35 | 20.89 | 12 | 9607 | 866 | 64488247 |
Bronchial secretion retention | 40.65 | 20.89 | 15 | 9604 | 2512 | 64486601 |
Rash maculo-papular | 40.25 | 20.89 | 42 | 9577 | 46984 | 64442129 |
Drug resistance | 38.70 | 20.89 | 36 | 9583 | 35066 | 64454047 |
Pneumonia pseudomonal | 37.23 | 20.89 | 17 | 9602 | 4886 | 64484227 |
Toxic epidermal necrolysis | 36.95 | 20.89 | 36 | 9583 | 37130 | 64451983 |
Nonspecific reaction | 32.62 | 20.89 | 12 | 9607 | 1991 | 64487122 |
Condition aggravated | 32.19 | 20.89 | 125 | 9494 | 372301 | 64116812 |
Leukocytosis | 31.03 | 20.89 | 33 | 9586 | 37707 | 64451406 |
Toxicity to various agents | 31.02 | 20.89 | 8 | 9611 | 363505 | 64125608 |
Chest discomfort | 30.74 | 20.89 | 59 | 9560 | 116047 | 64373066 |
Disease complication | 29.96 | 20.89 | 14 | 9605 | 4241 | 64484872 |
Pneumothorax | 28.89 | 20.89 | 26 | 9593 | 24272 | 64464841 |
Bronchospasm | 27.36 | 20.89 | 24 | 9595 | 21658 | 64467455 |
Toxic skin eruption | 25.66 | 20.89 | 22 | 9597 | 19262 | 64469851 |
Treatment noncompliance | 25.60 | 20.89 | 32 | 9587 | 43450 | 64445663 |
Sputum discoloured | 25.05 | 20.89 | 21 | 9598 | 17835 | 64471278 |
Superinfection | 24.95 | 20.89 | 12 | 9607 | 3874 | 64485239 |
Fall | 24.56 | 20.89 | 16 | 9603 | 416810 | 64072303 |
Bronchopulmonary aspergillosis allergic | 23.79 | 20.89 | 9 | 9610 | 1613 | 64487500 |
Dyspnoea | 23.48 | 20.89 | 185 | 9434 | 718489 | 63770624 |
Cystic fibrosis hepatic disease | 21.75 | 20.89 | 4 | 9615 | 39 | 64489074 |
Pain in extremity | 21.74 | 20.89 | 9 | 9610 | 303076 | 64186037 |
Fatigue | 20.89 | 20.89 | 51 | 9568 | 748679 | 63740434 |
None
Source | Code | Description |
---|---|---|
ATC | J01DF01 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Monobactams |
FDA CS | M0014030 | Monobactams |
FDA EPC | N0000175493 | Monobactam Antibacterial |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
CHEBI has role | CHEBI:36047 | antibacterial drugs |
CHEBI has role | CHEBI:50696 | PBP3 inhibitor |
CHEBI has role | CHEBI:88188 | allergenic drug |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Septicemia due to Escherichia coli | indication | 9323009 | |
Infection due to Pseudomonas aeruginosa | indication | 11218009 | |
Infection of skin AND/OR subcutaneous tissue | indication | 19824006 | |
Pneumonia due to Pseudomonas | indication | 41381004 | |
Peritonitis | indication | 48661000 | |
Lower respiratory tract infection | indication | 50417007 | |
Pneumonia due to Escherichia coli | indication | 51530003 | |
Klebsiella cystitis | indication | 60867007 | |
Urinary tract infectious disease | indication | 68566005 | |
Haemophilus influenzae pneumonia | indication | 70036007 | |
Infection due to Escherichia coli | indication | 71057007 | |
Bacterial infection due to Serratia | indication | 71120004 | |
Rhinoscleroma | indication | 72409005 | DOID:11336 |
Endometritis | indication | 78623009 | DOID:1002 |
Septicemia due to Serratia | indication | 82091000 | |
Female genital tract infection | indication | 125585007 | |
Infectious disease of abdomen | indication | 128070006 | |
Infection due to Enterobacteriaceae | indication | 128945009 | |
Bacterial infection due to Klebsiella pneumoniae | indication | 186435004 | |
Proteus pneumonia | indication | 195888009 | |
Bacterial peritonitis | indication | 197171003 | |
Proteus septicemia | indication | 300986008 | |
Escherichia coli urinary tract infection | indication | 301011002 | |
Proteus urinary tract infection | indication | 301012009 | |
Bacterial urinary infection | indication | 312124009 | |
Sepsis due to Pseudomonas | indication | 448813005 | |
Sepsis due to Gram negative bacteria | indication | 449082003 | |
Gram-Negative Aerobic Bacillary Pneumonia | indication | ||
Serratia Urinary Tract Infection | indication | ||
E. Coli Pelvic Inflammatory Disease | indication | ||
Enterobacter Pneumonia | indication | ||
Citrobacter Urinary Tract Infection | indication | ||
Skin and Skin Structure Proteus Infection | indication | ||
Skin and Skin Structure Pseudomonas Aeruginosa Infection | indication | ||
Haemophilus Influenzae Bronchitis | indication | ||
E. Coli Bronchitis | indication | ||
Respiratory Cystic Fibrosis with Pseudomonas aeruginosa Colonization | indication | ||
Skin and Skin Structure Serratia Infection | indication | ||
Inflammatory Disease of Female Pelvic Organs | indication | ||
Proteus Pelvic Inflammatory Disease | indication | ||
E. Coli Endometritis | indication | ||
Enterobacter Cloacae Bronchitis | indication | ||
Serratia Bronchitis | indication | ||
Pseudomonas Aeruginosa Bronchitis | indication | ||
Citrobacter Peritonitis | indication | ||
Aerobic Gram-Negative Bacteremia | indication | ||
E. Coli Peritonitis | indication | ||
Enterobacter Endometritis | indication | ||
Skin and Skin Structure Citrobacter Infection | indication | ||
Serratia Peritonitis | indication | ||
Enterobacter Pelvic Inflammatory Disease | indication | ||
Klebsiella Endometritis | indication | ||
Pseudomonas Aeruginosa Urinary Tract Infection | indication | ||
Klebsiella Pelvic Inflammatory Disease | indication | ||
Bacterial Exacerbation of Acute Bronchitis | indication | ||
Proteus Bronchitis | indication | ||
Proteus Endometritis | indication | ||
Klebsiella Pneumoniae Peritonitis | indication | ||
Bronchospasm | contraindication | 4386001 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Pseudomembranous enterocolitis | contraindication | 397683000 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 3.44 | acidic |
pKa2 | 2.83 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Peptidoglycan synthase FtsI | Enzyme | INHIBITOR | IC50 | 5.74 | WOMBAT-PK | CHEMBL | |||
Penicillin-binding protein 1A | Enzyme | INHIBITOR | IC50 | 5.32 | WOMBAT-PK | CHEMBL | |||
Penicillin-binding protein 1B | Enzyme | INHIBITOR | IC50 | 4.32 | WOMBAT-PK | CHEMBL | |||
Beta-lactamase | Enzyme | IC50 | 7.49 | CHEMBL | |||||
Efflux transporter; SugE | Transporter | IC50 | 8.22 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 8.22 | CHEMBL | |||||
Beta-lactamase | Enzyme | Ki | 8.15 | CHEMBL | |||||
AmpC | Unclassified | IC50 | 7.22 | CHEMBL | |||||
Beta-lactamase | Enzyme | Ki | 5.52 | CHEMBL | |||||
Penicillin-binding protein 1A | Enzyme | IC50 | 5.48 | CHEMBL | |||||
Beta-lactamase | Enzyme | Ki | 5.70 | CHEMBL |
ID | Source |
---|---|
D00240 | KEGG_DRUG |
827611-49-4 | SECONDARY_CAS_RN |
1272 | RXNORM |
C0004521 | UMLSCUI |
CHEBI:161680 | CHEBI |
CHEMBL158 | ChEMBL_ID |
CHEMBL3833340 | ChEMBL_ID |
D001398 | MESH_DESCRIPTOR_UI |
DB00355 | DRUGBANK_ID |
10763 | IUPHAR_LIGAND_ID |
5159 | INN_ID |
G2B4VE5GH8 | UNII |
5742832 | PUBCHEM_CID |
167898 | MMSL |
170132 | MMSL |
2813 | MMSL |
4239 | MMSL |
d00067 | MMSL |
002807 | NDDF |
013342 | NDDF |
4017762 | VANDF |
4037186 | VANDF |
AZR | PDB_CHEM_ID |
373297006 | SNOMEDCT_US |
387386004 | SNOMEDCT_US |
409132008 | SNOMEDCT_US |
409133003 | SNOMEDCT_US |
69918003 | SNOMEDCT_US |
734461007 | SNOMEDCT_US |
90614001 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
AZACTAM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0003-2560 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | NDA | 21 sections |
AZACTAM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0003-2570 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | NDA | 21 sections |
Aztreonam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-0829 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 23 sections |
Aztreonam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-0830 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 23 sections |
Aztreonam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-401 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 24 sections |
Aztreonam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-401 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 24 sections |
Aztreonam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-401 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 24 sections |
Aztreonam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-401 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 24 sections |
Aztreonam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-401 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 24 sections |
Aztreonam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-401 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 24 sections |
Aztreonam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-402 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 24 sections |
Aztreonam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-402 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 24 sections |
Aztreonam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-402 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 24 sections |
Aztreonam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-402 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 24 sections |
Aztreonam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-402 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 24 sections |
Aztreonam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-402 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 24 sections |